Quality of antibody responses by adults and young children to 13-valent pneumococcal conjugate vaccination and Streptococcus pneumoniae colonisation.
Avidity
Carriage
Colonisation
Opsonophagocytosis
PCV
Pneumococcal conjugate vaccine
Pneumococcus
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
28 11 2022
28 11 2022
Historique:
received:
30
06
2022
revised:
15
09
2022
accepted:
22
09
2022
pubmed:
10
10
2022
medline:
23
11
2022
entrez:
9
10
2022
Statut:
ppublish
Résumé
Childhood pneumococcal conjugate vaccine (PCV) protects against invasive pneumococcal disease caused by vaccine-serotype (VT) Streptococcus pneumoniae by generating opsonophagocytic anti-capsular antibodies, but how vaccination protects against and reduces VT carriage is less well understood. Using serological samples from PCV-vaccinated Malawian individuals and a UK human challenge model, we explored whether antibody quality (IgG subclass, opsonophagocytic killing, and avidity) is associated with protection from carriage. Following experimental challenge of adults with S. pneumoniae serotype 6B, 3/21 PCV13-vaccinees were colonised with pneumococcus compared to 12/24 hepatitis A-vaccinated controls; PCV13-vaccination induced serotype-specific IgG, IgG1, and IgG2, and strong opsonophagocytic responses. However, there was no clear relationship between antibody quality and protection from carriage or carriage intensity after vaccination. Similarly, among PCV13-vaccinated Malawian infants there was no relationship between serotype-specific antibody titre or quality and carriage through exposure to circulating serotypes. Although opsonophagocytic responses were low in infants, antibody titre and avidity to circulating serotypes 19F and 6A were maintained or increased with age. These data suggest a complex relationship between antibody-mediated immunity and pneumococcal carriage, and that PCV13-driven antibody quality may mature with age and exposure.
Identifiants
pubmed: 36210249
pii: S0264-410X(22)01190-2
doi: 10.1016/j.vaccine.2022.09.069
pmc: PMC10615833
pii:
doi:
Substances chimiques
Pneumococcal Vaccines
0
Vaccines, Conjugate
0
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7201-7210Subventions
Organisme : Wellcome Trust
ID : 206545/Z/17/Z
Pays : United Kingdom
Organisme : Department of Health
ID : 16/136/46
Pays : United Kingdom
Organisme : Department of Health
ID : NIHR300039
Pays : United Kingdom
Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
mSphere. 2019 Jun 19;4(3):
pubmed: 31217308
Infect Immun. 2001 Jan;69(1):336-44
pubmed: 11119522
Clin Vaccine Immunol. 2013 Jul;20(7):1034-40
pubmed: 23658394
Clin Vaccine Immunol. 2006 Sep;13(9):1004-9
pubmed: 16960111
J Infect Dis. 2012 May 1;205(9):1408-16
pubmed: 22457293
Nat Commun. 2020 May 6;11(1):2222
pubmed: 32376860
J Infect Dis. 2004 Aug 1;190(3):545-50
pubmed: 15243930
PLoS One. 2013 Sep 23;8(9):e74906
pubmed: 24086394
Am J Respir Crit Care Med. 2016 Dec 15;194(12):1523-1531
pubmed: 27403678
Clin Diagn Lab Immunol. 1997 Mar;4(2):168-72
pubmed: 9067650
Vaccine. 2015 Dec 16;33(51):7144-7151
pubmed: 26592141
BMJ Open. 2017 Jul 2;7(6):e016283
pubmed: 28674145
Vaccine. 2007 May 10;25(19):3816-26
pubmed: 17368878
Clin Diagn Lab Immunol. 2003 Jul;10(4):514-9
pubmed: 12853378
Am J Respir Crit Care Med. 2015 Oct 1;192(7):853-8
pubmed: 26114410
J Infect Dis. 1998 Apr;177(4):1112-5
pubmed: 9534995
Lancet Infect Dis. 2015 May;15(5):535-43
pubmed: 25801458
Clin Infect Dis. 2018 Mar 5;66(6):913-920
pubmed: 29069415
J Infect Dis. 1998 Jun;177(6):1614-21
pubmed: 9607841
J Clin Invest. 2019 Jul 30;129(10):4523-4538
pubmed: 31361601
Vaccine. 2017 Aug 16;35(35 Pt B):4652-4657
pubmed: 28739116
Lancet Glob Health. 2021 Jul;9(7):e989-e998
pubmed: 34143997
Front Immunol. 2014 Oct 20;5:520
pubmed: 25368619
J Infect Dis. 2000 Sep;182(3):965-9
pubmed: 10950799
PLoS One. 2015 Dec 10;10(12):e0144739
pubmed: 26658902
Vaccine. 2019 Dec 3;37(51):7470-7477
pubmed: 31575493
Clin Vaccine Immunol. 2016 Apr 04;23(4):379-85
pubmed: 26912783
BMC Med. 2019 Dec 5;17(1):219
pubmed: 31801542
Infect Immun. 1999 Sep;67(9):4935-8
pubmed: 10456954
Vaccine. 2013 Dec 2;31(49):5834-42
pubmed: 24120678
Vaccine. 2013 Dec 17;32(1):133-45
pubmed: 23684824
J Immunol Methods. 2018 Oct;461:37-43
pubmed: 30098317
Vaccine. 2015 Jan 29;33(5):628-34
pubmed: 25541213
Clin Vaccine Immunol. 2014 Jun;21(6):904-7
pubmed: 24759650
Vaccine. 2006 Jul 7;24(27-28):5637-44
pubmed: 16730399
Clin Infect Dis. 2021 Feb 1;72(3):448-454
pubmed: 31995183
J Vis Exp. 2013 Feb 15;(72):
pubmed: 23439027
Expert Rev Vaccines. 2012 Jul;11(7):841-55
pubmed: 22913260
Lancet Infect Dis. 2022 Dec;22(12):1737-1747
pubmed: 36029796
Lancet Infect Dis. 2016 Jun;16(6):703-711
pubmed: 26897105
Mucosal Immunol. 2017 Mar;10(2):385-394
pubmed: 27579859
Vaccine. 2011 Jun 15;29(27):4499-506
pubmed: 21539882
J Clin Immunol. 2013 May;33(4):847-56
pubmed: 23378166
J Immunol. 2003 Jun 15;170(12):6158-64
pubmed: 12794146
Clin Infect Dis. 1999 Aug;29(2):281-8
pubmed: 10476727
Clin Infect Dis. 2007 May 1;44(9):1173-9
pubmed: 17407035
Infect Immun. 1999 May;67(5):2366-70
pubmed: 10225896
Lancet Infect Dis. 2014 Sep;14(9):839-46
pubmed: 25042756
Clin Vaccine Immunol. 2012 Oct;19(10):1618-23
pubmed: 22875604